Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Open Access
- 1 June 2020
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 111 (6), 1910-1920
- https://doi.org/10.1111/cas.14401
Abstract
Pemetrexed (PEM) is a useful drug that can be combined with immune checkpoint blockade therapy for treatment of patients with advanced non-small-cell lung cancer (NSCLC). However, its effects on anti-cancer immunity, especially the sensitivity of NSCLC cells to cytotoxic immune cells, have not been fully investigated. In this study, we examined the effects of PEM on the sensitivity of human NSCLC cells to two different types of cytotoxic immune cells. Pre-treatment with PEM increased the sensitivity of two NSCLC cell lines, PC9 and A549, to activated T cells and natural killer (NK) cells, and decreased the expression of anti-apoptotic proteins, including XIAP and Mcl-1. In addition, PEM treatment increased the cell surface expression of programmed death-ligand 1 (PD-L1) on PC9 cells. PEM-induced upregulation of PD-L1 on PC9 cells was at least partially ascribed to activation of ERK and the NF kappa B pathway. In contrast, PEM treatment increased the expression of UL16-binding proteins (ULBP), ligands for the NKG2D NK receptor, on PC9 and A549 cells, as well as the induction of senescence. Although the addition of anti-programmed cell death 1 antibody showed no effect on the sensitivity of PEM-treated PC9 and A549 cells to activated T cells, that of anti-NKG2D antibody decreased the enhanced sensitivity of PEM-treated A549 cells to NK cells. These results indicate that PEM can effectively sensitize human NSCLC cells to cytotoxic immune cells while modulating the expression of immune-regulatory molecules.Funding Information
- Japan Society for the Promotion of Science KAKENHI (16K19313, 17K07217)
- Shimane University "SUIGAN" Project
This publication has 36 references indexed in Scilit:
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cellsJCI Insight, 2013
- Therapy-Induced Senescence in CancerJNCI Journal of the National Cancer Institute, 2010
- The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor SuppressionAnnual review of pathology, 2010
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attackBlood, 2006
- Regulators of apoptosis: suitable targets for immune therapy of cancerNature Reviews Drug Discovery, 2005
- NFAT and NF-κB factors—the distant relativesThe International Journal of Biochemistry & Cell Biology, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Cell Surface Organization of Stress-inducible Proteins ULBP and MICA That Stimulate Human NK Cells and T Cells via NKG2DThe Journal of Experimental Medicine, 2004
- Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells.JCI Insight, 1998